May 14, 2025, 12:31

Cancer Research UK: Therapeutic Catalyst

The Therapeutic Catalyst supports the early translation of high-impact cancer research discoveries into novel therapeutics. The scheme funds projects with strong therapeutic potential across all cancer types, aiming to de-risk early ideas and validate targets or technologies. Projects are executed collaboratively between the academic researcher and Cancer Research Horizons drug discovery labs.

Eligibility Criteria:

Open to academic researchers worldwide
Must have an independent lab at a university or research institute
Suitable for early career, mid-career, established researchers, and clinicians
Projects must fall within the scheme’s drug discovery scope

Funding Details:

Up to £250,000 (USD 310,000) per project
Funding period: Up to 18 months
Covers academic staff time and research-related expenses
Funded activities may include assays, target validation, and early therapeutic feasibility studies

Deadline:

Expression of Interest deadline: 06 June 2025
3 application rounds annually: February, June, October
Contact the Therapeutic Catalyst team early for discussion and feedback

More Information:

Expression of Interest Form
Contact: [email protected]

academic-industry collaboration cancer Cancer Research Horizons cancer therapeutics drug discovery early-stage drug development OncoDaily Oncology oncology funding target validation therapeutic catalyst translational research

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot